"Quinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011804
|
| MeSH Number(s) |
D03.633.100.810
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinolines".
Below are MeSH descriptors whose meaning is more specific than "Quinolines".
This graph shows the total number of publications written about "Quinolines" by people in this website by year, and whether "Quinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 4 | 0 | 4 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 4 | 1 | 5 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 4 | 5 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 6 | 1 | 7 |
| 2018 | 4 | 0 | 4 |
| 2019 | 2 | 3 | 5 |
| 2020 | 1 | 2 | 3 |
| 2021 | 5 | 2 | 7 |
| 2022 | 1 | 3 | 4 |
| 2023 | 2 | 0 | 2 |
| 2024 | 4 | 2 | 6 |
| 2025 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolines" by people in Profiles.
-
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia. 2026 Feb; 40(2):304-313.
-
Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
No evidence of pitavastatin effect on muscle area or density among people with HIV. AIDS. 2025 Nov 15; 39(14):2031-2039.
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. Mol Cancer. 2025 Jun 11; 24(1):175.
-
Antibiofilm properties of 4-hydroxy-3-methyl-2-alkenylquinoline, a novel Burkholderia-derived alkaloid. mSphere. 2025 May 27; 10(5):e0108124.
-
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2024 12 01; 10(12):1645-1653.
-
Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease. J Nucl Med. 2024 Nov 01; 65(11):1789-1794.
-
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial. JAMA Netw Open. 2024 10 01; 7(10):e2439332.
-
Symmetry breaking of fluorophore binding to a G-quadruplex generates an RNA aptamer with picomolar KD. Nucleic Acids Res. 2024 Aug 12; 52(14):8039-8051.